Iovance Biotherapeutics (IOVA)
NASDAQ:IOVA
Want to see IOVA full AI Analyst Report?
IOVA Stock Chart & Stats
$3.86
-$0.33(-4.53%)
At close: 4:00 PM EST
$3.86
-$0.33(-4.53%)
Day’s Range― - ―
52-Week Range$1.66 - $5.63
Previous CloseN/A
Volume2.95M
Average Volume (3M)14.69M
Market Cap
$1.83B
Enterprise Value$1.32B
Total Cash (Recent Filing)$313.44M
Total Debt (Recent Filing)$46.78M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Aug 06, 2026EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding446,502,400
10 Day Avg. Volume12,327,159
30 Day Avg. Volume14,691,414
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.40
Price to Sales (P/S)3.70
P/FCF Ratio-2.90
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue4.61
Enterprise Value/Gross Profit4.02
Enterprise Value/Ebitda-4.03
Forecast
1Y Price Target
$8.83Price Target Upside128.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.55
Revenue Forecast (FY)$359.76M
Bulls Say, Bears Say
Bulls Say
Commercial Revenue MomentumSustained high single‑quarter growth (Q1 revenue +45% YoY) indicates the core product is gaining durable market adoption. This supports expanding treatment volumes, strengthens payer engagement, and underpins multi‑year revenue scaling required to approach profitability.
In‑house Manufacturing ControlBringing Amtagvi manufacturing fully in‑house via a modular iCTC facility reduces reliance on external CDMOs, improves supply reliability, and enables unit cost control and scale. That structural capability supports margin expansion and international rollouts over the medium term.
Balance Sheet Resilience & RunwayRelatively low leverage and a meaningful equity base, paired with management's guidance of cash to fund operations into 2028 and declining R&D, reduce near‑term refinancing pressure and give time to execute commercialization and margin improvement plans.
Bears Say
Large Cash BurnPersistent, sizable negative operating and free cash flow means the business consumes material liquidity each year. Even with runway assumptions, continuing burn necessitates external funding or stricter cash discipline, creating dilution risk and execution constraints until breakeven is achieved.
Deep Ongoing LossesLarge cumulative net losses and deeply negative margins signal the company remains far from profitability. Continued negative returns on equity imply shareholder value erosion until sustained revenue scale and margin expansion offset fixed and operating costs.
Execution & Regulatory DependenceCommercial upside is contingent on successful accelerated approvals, trial enrollment and timely launches. Delays or adverse regulatory outcomes could push back peak sales, raise funding needs, and increase the likelihood of additional financing or strategic trade‑offs.
Iovance Biotherapeutics News
IOVA FAQ
What was Iovance Biotherapeutics’s price range in the past 12 months?
Iovance Biotherapeutics lowest stock price was $1.66 and its highest was $5.63 in the past 12 months.
What is Iovance Biotherapeutics’s market cap?
Iovance Biotherapeutics’s market cap is $1.83B.
When is Iovance Biotherapeutics’s upcoming earnings report date?
Iovance Biotherapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 63 days.
How were Iovance Biotherapeutics’s earnings last quarter?
Iovance Biotherapeutics released its earnings results on May 07, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.154 by -$0.036.
Is Iovance Biotherapeutics overvalued?
According to Wall Street analysts Iovance Biotherapeutics’s price is currently Undervalued.
Does Iovance Biotherapeutics pay dividends?
Iovance Biotherapeutics does not currently pay dividends.
What is Iovance Biotherapeutics’s EPS estimate?
Iovance Biotherapeutics’s EPS estimate is -0.13.
How many shares outstanding does Iovance Biotherapeutics have?
Iovance Biotherapeutics has 446,502,400 shares outstanding.
What happened to Iovance Biotherapeutics’s price movement after its last earnings report?
Iovance Biotherapeutics reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.154. Following the earnings report the stock price went down -13.203%.
Which hedge fund is a major shareholder of Iovance Biotherapeutics?
Currently, no hedge funds are holding shares in IOVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Iovance Biotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.83 (128.84% Upside)
$8.83 (128.84% Upside)
Blogger Sentiment
Bullish
IOVA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 571.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 0.7%
Last 30 Days ▲ 0.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
132.95%
12-Months-Change
Fundamentals
Return on Equity
-50.17%
Trailing 12-Months
Asset Growth
-4.25%
Trailing 12-Months
Company Description
Iovance Biotherapeutics
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
IOVA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and meaningful operational progress: high single-quarter revenue growth (~45% YoY), robust Amtagvi demand (+38% YoY), tighter Q2/full-year guidance, expanded manufacturing control, R&D cost reductions, extended cash runway into 2028, and encouraging early clinical signals (e.g., 40% ORR in serous endometrial cancer). Near-term headwinds include a one-time facility-related margin hit (Q1 gross margin ~41%), some quarter-to-quarter revenue volatility in Proleukin, continued use of ATM financing, and the usual clinical/regulatory and enrollment execution risks. Overall, the positives—notably accelerating commercial traction, pipeline advances, and improved cost discipline—substantially outweigh the listed challenges.View all IOVA earnings summariesIOVA Stock 12 Month Forecast
Average Price Target
$8.83
▲(128.84% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Vir Biotechnology
―
Immatics
―
Nuvation Bio
―
Amylyx Pharmaceuticals Inc
―
Ownership Overview
0.32% Insiders
11.58% Mutual Funds
15.99% Other Institutional Investors
57.63% Public Companies and Individual Investors